Thr180
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr180  -  XIAP (human)

Site Information
WPDYAHLtPRELASA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3801500

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , breast ( 2 ) , HCT116 (intestinal) ( 1 ) , HeLa (cervical) ( 1 , 3 , 4 ) , SW480 (intestinal) ( 1 )

Upstream Regulation
Kinases, in vitro:
GSK3B (human) ( 1 )

Downstream Regulation
Effects of modification on XIAP:
enzymatic activity, induced ( 1 ) , ubiquitination ( 1 )
Induce interaction with:
TLE3 (human) ( 1 )

References 

1

Ng VH, et al. (2018) Phosphorylation of XIAP at threonine 180 controls its activity in Wnt signaling. J Cell Sci
29678905   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Moritz A (2008) CST Curation Set: 5077; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info